There is an obvious trend to a higher incidence in the US trials (about 40%) than in German (about 25%) and Asian trials (about 17%), but the differences from trial to trial in each area are very wide.
← all excerpts
Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations.
1
—
—